Renaissance Technologies’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-1,809,489
| Closed | -$1.88M | – | 3898 |
|
|
2019
Q1 | $1.88M | Buy |
1,809,489
+590,882
| +48% | +$481K | ﹤0.01% | 2337 |
|
|
2018
Q4 | $911K | Buy |
1,218,607
+401,207
| +49% | +$604K | ﹤0.01% | 2621 |
|
|
2018
Q3 | $1.73M | Buy |
817,400
+60,000
| +8% | +$144K | ﹤0.01% | 2342 |
|
|
2018
Q2 | $1.75M | Buy |
757,400
+59,300
| +8% | +$173K | ﹤0.01% | 2339 |
|
|
2018
Q1 | $2.22M | Buy |
698,100
+168,800
| +32% | +$465K | ﹤0.01% | 2271 |
|
|
2017
Q4 | $2.17M | Buy |
529,300
+117,700
| +29% | +$512K | ﹤0.01% | 2293 |
|
|
2017
Q3 | $1.86M | Buy |
411,600
+42,004
| +11% | +$170K | ﹤0.01% | 2326 |
|
|
2017
Q2 | $1.23M | Sell |
369,596
-164,004
| -31% | -$680K | ﹤0.01% | 2494 |
|
|
2017
Q1 | $4.91M | Buy |
533,600
+64,300
| +14% | +$565K | 0.01% | 1688 |
|
|
2016
Q4 | $3.62M | Buy |
469,300
+217,700
| +87% | +$2M | 0.01% | 1879 |
|
|
2016
Q3 | $2.88M | Buy |
+251,600
| New | +$2.93M | 0.01% | 1977 |
|
|
2015
Q4 | – | Sell |
-67,700
| Closed | -$1.12M | – | 3627 |
|
|
2015
Q3 | $1.12M | Buy |
67,700
+42,758
| +171% | +$857K | ﹤0.01% | 2321 |
|
|
2015
Q2 | $561K | Buy |
+24,942
| New | +$615K | ﹤0.01% | 2685 |
|
|
2015
Q1 | – | Sell |
-20,675
| Closed | -$450K | – | 3559 |
|
|
2014
Q4 | $450K | Sell |
20,675
-19,435
| -48% | -$398K | ﹤0.01% | 2465 |
|
|
2014
Q3 | $759K | Sell |
40,110
-19,090
| -32% | -$384K | ﹤0.01% | 2164 |
|
|
2014
Q2 | $1.38M | Buy |
+59,200
| New | +$1.46M | ﹤0.01% | 1916 |
|
Renaissance Technologies's OMED Position: Q2 2019 in Review
Renaissance Technologies sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 1,809,489 shares — an estimated $1.88M sold.
Renaissance Technologies first reported a position in OMED in Q2 2014 and held it in 16 quarters. The position peaked at $4.91M in Q1 2017. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Renaissance Technologies reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Renaissance Technologies sold 1,809,489 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $1.88M.
- Renaissance Technologies first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 16 quarters.
- Renaissance Technologies's OncoMed Pharmaceuticals, Inc. position peaked at $4.91M in Q1 2017.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.